Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05387083 · ClinicalTrials.gov registry record · Phase 2
A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05
A Phase 2 study, sponsored by Tarsus Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT05387083 is a Phase 2 study that has completed, run by Tarsus Pharmaceuticals. The registered enrollment target is 30 participants.
The verdict
NCT05387083, a Phase 2 study, has completed, sponsored by Tarsus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human skin.
Interventions
- DRUG Placebo Comparator
- DRUG Low Dose TP-05
- DRUG High Dose TP-05
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2022-12-12 |
| Est. Completion | 2024-06-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05387083
The ClinicalTrials.gov registry entry for NCT05387083 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tarsus Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo Comparator is the first listed.
NCT05387083 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05387083 about?
NCT05387083 is a clinical study titled "A Human Tick Kill Study to Investigate the Safety, Tolerability, and Whole Blood Concentration of TP-05". This is a Phase 2a, randomized, double-blind, proof-of-concept, single-center study evaluating the safety, tolerability, and whole blood concentration of TP-05 (lotilaner) in the killing of ticks after they have attached to human skin.
What is the current status of trial NCT05387083?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2022-12-12. Estimated completion is 2024-06-26.
What interventions are being tested in trial NCT05387083?
The interventions under investigation include: Placebo Comparator (DRUG), Low Dose TP-05 (DRUG), High Dose TP-05 (DRUG).
Who is sponsoring clinical trial NCT05387083?
This trial is sponsored by Tarsus Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.